EDBI Logo
|  

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase(HDAC) Inhibitor SB939

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)

Related Posts

Could Singapore become the next global biotech hub?

  • 02 05 2023
  • |
Read More

EdgeQ Closes $75M Series-B Investment and Ramps to Customers’ Demand for Its Award-Winning 5G+AI Base Station-on-a-Chip for 5G Networks

  • 02 05 2023
  • |
Read More

Proxtera announces successful first close, of Series Seed round of funding with Ant Group, CerraCap Ventures, and EDBI

  • 30 03 2023
  • |
Read More

What to watch in the biomedical space over the next five years

  • 23 02 2023
  • |
Read More

The Upside – EDBI E-Newsletter 2022 Q4

  • 10 01 2023
  • |
Read More

Our Inaugural Sustainability Report 2021/2022

  • 28 10 2022
  • |
Read More

Join our community!

Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.

Subscribe now

Investing in high-growth technologies that shape the future economic pillars of Singapore since 1991.

About EDBI

Team

Portfolio

News and Insights

Careers

Contact Us

Linkedin Youtube

© 2023 EDBI. All rights reserved.